Display options
Cite
Charalampopoulos A, Howard LS, Tzoulaki I, et al. Response to pulmonary arterial hypertension drug therapies in patients with pulmonary arterial hypertension and cardiovascular risk factors. Pulm Circ. 2014;4(4):669-78doi: 10.1086/678512.
Charalampopoulos, A., Howard, L. S., Tzoulaki, I., Gin-Sing, W., Grapsa, J., Wilkins, M. R., Davies, R. J., Nihoyannopoulos, P., Connolly, S. B., & Gibbs, J. S. (2014). Response to pulmonary arterial hypertension drug therapies in patients with pulmonary arterial hypertension and cardiovascular risk factors. Pulmonary circulation, 4(4), 669-78. https://doi.org/10.1086/678512
Charalampopoulos, Athanasios, et al. "Response to pulmonary arterial hypertension drug therapies in patients with pulmonary arterial hypertension and cardiovascular risk factors." Pulmonary circulation vol. 4,4 (2014): 669-78. doi: https://doi.org/10.1086/678512
Charalampopoulos A, Howard LS, Tzoulaki I, Gin-Sing W, Grapsa J, Wilkins MR, Davies RJ, Nihoyannopoulos P, Connolly SB, Gibbs JS. Response to pulmonary arterial hypertension drug therapies in patients with pulmonary arterial hypertension and cardiovascular risk factors. Pulm Circ. 2014 Dec;4(4):669-78. doi: 10.1086/678512. PMID: 25610602; PMCID: PMC4278626.
Copy Download .nbib Format: NLM
Share it on

Pulm Circ. 2014 Dec;4(4):669-78. doi: 10.1086/678512.

Response to pulmonary arterial hypertension drug therapies in patients with pulmonary arterial hypertension and cardiovascular risk factors.

Pulmonary circulation

Athanasios Charalampopoulos, Luke S Howard, Ioanna Tzoulaki, Wendy Gin-Sing, Julia Grapsa, Martin R Wilkins, Rachel J Davies, Petros Nihoyannopoulos, Susan B Connolly, J Simon R Gibbs

Affiliations

  1. National Pulmonary Hypertension Service, Hammersmith Hospital, Imperial College Healthcare National Health Service (NHS) Trust, London, United Kingdom.
  2. Imperial College London, London, United Kingdom ; University of Ioannina, Ioannina, Greece.
  3. Imperial College London, London, United Kingdom ; King's Lynn and Papworth Hospitals, Cambridge, United Kingdom ; Echocardiography Department, Hammersmith Hospital, Imperial College Healthcare NHS Trust, London, United Kingdom.
  4. Imperial College London, London, United Kingdom.
  5. Imperial College London, London, United Kingdom ; Echocardiography Department, Hammersmith Hospital, Imperial College Healthcare NHS Trust, London, United Kingdom.
  6. Cardiology Department, Imperial College Healthcare NHS Trust, London, United Kingdom ; National Heart and Lung Institute, Imperial College London, London, United Kingdom.
  7. National Pulmonary Hypertension Service, Hammersmith Hospital, Imperial College Healthcare National Health Service (NHS) Trust, London, United Kingdom ; National Heart and Lung Institute, Imperial College London, London, United Kingdom.

PMID: 25610602 PMCID: PMC4278626 DOI: 10.1086/678512

Abstract

The age at diagnosis of pulmonary arterial hypertension (PAH) and the prevalence of cardiovascular (CV) risk factors are increasing. We sought to determine whether the response to drug therapy was influenced by CV risk factors in PAH patients. We studied consecutive incident PAH patients (n = 146) between January 1, 2008, and July 15, 2011. Patients were divided into two groups: the PAH-No CV group included patients with no CV risk factors (obesity, systemic hypertension, type 2 diabetes mellitus, permanent atrial fibrillation, mitral and/or aortic valve disease, and coronary artery disease), and the PAH-CV group included patients with at least one. The response to PAH treatment was analyzed in all the patients who received PAH drug therapy. The PAH-No CV group included 43 patients, and the PAH-CV group included 69 patients. Patients in the PAH-No CV group were younger than those in the PAH-CV group (P < 0.0001). In the PAH-No CV group, 16 patients (37%) improved on treatment and 27 (63%) did not improve, compared with 11 (16%) and 58 (84%) in the PAH-CV group, respectively (P = 0.027 after adjustment for age). There was no difference in survival at 30 months (P = 0.218). In conclusion, in addition to older age, CV risk factors may predict a reduced response to PAH drug therapy in patients with PAH.

Keywords: cardiovascular risk factors; pulmonary arterial hypertension; pulmonary arterial hypertension–targeted treatment

References

  1. Acta Pharmacol Sin. 2011 Apr;32(4):441-8 - PubMed
  2. JAMA. 2013 Mar 27;309(12):1268-77 - PubMed
  3. J Card Fail. 2005 Feb;11(1):12-20 - PubMed
  4. Eur Heart J. 2009 Oct;30(20):2493-537 - PubMed
  5. Am Heart J. 1997 Jul;134(1):44-54 - PubMed
  6. N Engl J Med. 2005 Nov 17;353(20):2148-57 - PubMed
  7. J Am Coll Cardiol. 2003 Apr 16;41(8):1387-93 - PubMed
  8. Circulation. 2012 Jan 17;125(2):289-97 - PubMed
  9. Am J Respir Crit Care Med. 2002 Jul 1;166(1):111-7 - PubMed
  10. Am J Respir Crit Care Med. 2012 Oct 15;186(8):790-6 - PubMed
  11. Eur Respir J. 2011 May;37(5):1096-103 - PubMed
  12. Am J Hypertens. 2008 Nov;21(11):1258-63 - PubMed
  13. Eur Respir J. 2012 Apr;39(4):945-55 - PubMed
  14. Int J Cardiol. 2002 Oct;85(2-3):195-7 - PubMed
  15. J Am Soc Echocardiogr. 2010 Jul;23 (7):685-713; quiz 786-8 - PubMed
  16. Circ Heart Fail. 2013 Mar;6(2):184-92 - PubMed
  17. Lancet. 2003 Sep 6;362(9386):777-81 - PubMed
  18. N Engl J Med. 2008 Dec 4;359(23 ):2456-67 - PubMed
  19. Eur Heart J. 1997 Dec;18(12):1977-87 - PubMed
  20. Chest. 2010 Feb;137(2):376-87 - PubMed
  21. Ann Intern Med. 1987 Aug;107(2):216-23 - PubMed
  22. J Cardiovasc Dis Res. 2011 Oct;2(4):213-22 - PubMed
  23. Eur Heart J. 2007 Oct;28(20):2539-50 - PubMed
  24. Circulation. 2013 Jul 30;128(5):502-11 - PubMed
  25. Chest. 2004 Jul;126(1 Suppl):78S-92S - PubMed
  26. Circ Heart Fail. 2011 May;4(3):257-65 - PubMed
  27. Circulation. 2007 Oct 2;116(14):1555-62 - PubMed
  28. Eur J Echocardiogr. 2010 Jul;11(6):523-9 - PubMed
  29. Circulation. 2011 Jul 12;124(2):164-74 - PubMed
  30. Circulation. 2004 Jun 15;109(23):2839-43 - PubMed
  31. Circulation. 2007 Jul 17;116(3):238-48 - PubMed
  32. Eur Heart J. 2010 Oct;31(19):2369-429 - PubMed
  33. Chest. 2009 Jul;136(1):31-6 - PubMed
  34. Clin Cardiol. 2011 Aug;34(8):483-7 - PubMed
  35. J Am Coll Cardiol. 2009 Apr 28;53(17):1573-619 - PubMed
  36. Circulation. 2006 Aug 1;114(5):e84-231 - PubMed
  37. J Am Coll Cardiol. 2013 Jul 23;62(4):263-71 - PubMed
  38. Chest. 2008 Feb;133(2):358-62 - PubMed
  39. Eur J Pharmacol. 2006 Aug 7;542(1-3):141-7 - PubMed
  40. J Am Coll Cardiol. 2007 Nov 27;50(22):2136-44 - PubMed
  41. N Engl J Med. 2002 Mar 21;346(12):896-903 - PubMed
  42. Eur J Heart Fail. 2012 Sep;14(9):1067-74 - PubMed
  43. N Engl J Med. 1996 Feb 1;334(5):296-301 - PubMed
  44. J Am Coll Cardiol. 2011 Mar 22;57(12):1368-74 - PubMed
  45. Blood Press. 2012 Dec;21(6):331-7 - PubMed
  46. Am J Hypertens. 2007 Dec;20(12 ):1283-90 - PubMed
  47. Int J Cardiol. 2013 Sep 30;168(2):871-80 - PubMed

Publication Types